Club Level Highlight

Post Archives

A Major Milestone for Johnson Matthey’s Pennsylvania Clean Air Manufacturing Plant

Symbolising trade and investment between the United Kingdom and the surrounding South Pennsylvania region, look no further than Johnson Matthey’s Devon manufacturing plant, celebrating its 50th birthday.  

A leader in sustainable technology solutions, the roots of Johnson Matthey’s Devon plant, in Wayne PA, stretch back to 1974, which has remained key to the company’s largest Clean Air business ever since.  

The story charts back to the 1950s, when the California Institute of Technology identified vehicle exhaust emissions as a significant contributor to smog – a form of air pollution. Legislation progressively tightened emission limits, culminating in the groundbreaking Clean Air Act of 1970 which mandated substantial reductions.  

JM’s scientists set to work prototyping honeycomb catalysts in Europe, before patenting an autocatalyst, with a proof of concept on a 1500cc Chrysler Avenger, sold in the US as a Plymouth Cricket. Viable production followed, through combining a conveyor belt and waterfall washcoat solution, with the Devon doors opening in March 1974 – an identical replica of its Royston sibling, situated in Hertfordshire, England, UK.  

Today, the plant is home to a team of c.500 workers, and continues to serve as an integral part of the community and local commerce. The manufacturing site is a unionized facility with a rich history and partnership with the United Steelworkers. To date, the site has produced and shipped over 500 million catalysts, which has resulted in preventing millions of metric tons of harmful pollutants from entering the atmosphere and cleaning the air.  

Quote from Zachery Taormina, Plant Manager – Clean Air North America: “The products we make really make a difference in the world and that’s something that everyone in Devon takes pride in.  While it feels good to make a difference in our work, our people are what truly makes JM such a special place and organization to work for. There’s a collective sense of purpose and we’re committed to working as a team to proudly serve our customers with world-class catalyst technologies to serve both the automotive and stationary sources with emission solutions!” 

And while 50 years is a proud milestone, the focus is firmly on the future, with an onsite technology center continuing to innovate and progress the next generation of emissions solutions, and invest in the novel use of technology in new applications and markets – a big opportunity. The US and the Greater Philadelphia region will continue to be a focused growth area for Johnson Matthey, which has a history in the area dating back to 1909. 

Quote from Krista Johnson, US President: “The dedication and commitment that brought us to this moment is absolutely worthy of celebration.  The men and women who built and sustained Devon have our thanks.  It is on their shoulders that we can see the bright future for this plant and for JM USA; a future in which we continue to provide the products, technology, collaboration, and partnership that will bring sustainable energy and goods to the world far into the future.  Here’s to the next 50 years!” 

Doing Business in the U.S.: What All Businesses Need to Know

Each new year brings a sense of hope, energy and opportunity. For all businesses, that means a renewed focus on growth. That often means going global. Organizations decide to be global for a combination of reasons — access to new markets; diversification; to gain a competitive edge. Sometimes an organization’s first step into an international market is at the beckoning of a leading customer’s request.

Indeed, the opportunity to grow top-line revenues, achieve greater economies of scale and strengthen the overall enterprise is great. However, as we look at the changing landscape of global trade, we see that it’s not what globalization and global pressures will do for an organization but what it’ll do to them if they don’t properly prepare, plan and adapt.

Baker Tilly understands change is a trigger for growth-minded organizations to evaluate their strategies and the tactics that follow. In this article we offer a road map to guide companies looking to do business in the U.S.

Small business cybersecurity risk: cyberattacks don’t care how big your business is

When it comes to cyberattacks, the assumption is only large organizations like banks, hospital systems and multinational companies are affected. But that just isn’t the case. The pandemic forced all types of businesses to quickly move online whether or not they had the right cybersecurity in place, opening small businesses to increased risk.

In fact, the FBI’s cyber division reported a 400% increase in cyberattacks in 2020 over pre-coronavirus times, so it’s no surprise that 58% of small businesses have experienced at least one security or data breach, according to a 2021 report from the Identity Theft Resource Center (ITRC).

And if your company doesn’t have a business continuity plan in place, any kind of breach can be costly: Nearly 45% of small businesses paid between $250,000 and $500,000 to cover the costs of the breach, while 16% spent between $500,000 and $1 million.

Just the immediate aftermath of a cyberattack can be paralyzing to a small business since their systems could be down for possibly days or even a few weeks. All of a sudden, it’s not only customers that are affected, but also employees and vendors.

Furthermore, one frightening statistic from Cybercrime magazine said that 60% of small businesses struggle to recover and have to close up shop within six months of a data breach or cyberattack.

Should the business survive, it typically takes them years to recover. The report from the ITRC said 42% needed one to two years to return to normal, and 28% needed three to five years to fully recover.

We haven’t even addressed the possibility of being sued by one of your customers for compromising their data, but that is a very real and very costly possibility.

All of that said, small businesses can avoid the bulk of these issues with proper planning.

First, a small business needs to acknowledge it could be a victim of a cyberattack. The vast majority of small businesses have no cyber liability insurance or any money set aside in case of such an attack, much less a comprehensive plan in place for how to deal with one.

Often, small businesses don’t employ IT staff or if they have, they designated someone as their technology support person who isn’t actually qualified in the first place. Sometimes, they outsource the role but don’t spend time determining what that third party’s responsibilities are and aren’t aware that backing up data or updating certain systems are not considered part of their purview. Read more.

Managing multistate HR and payroll compliance for today’s remote workforce

A little more than three years ago, everything changed about the way we live and work.

One day, we were talking face-to-face with our friends and family. The next day, we were six feet apart. Masks quickly became a staple of our everyday lives. And the idea of going to restaurants, schools and stores suddenly became more of a fantasy than a reality.

Additionally, there was a massive shift in the way we work. The COVID-19 pandemic rattled everything we knew about our jobs – not only the location from which most of us worked, but also the way we communicated with coworkers, the use of technology to do our jobs and many other aspects, including the way we attract, hire and retain employees.

These changes were presented as short-term realities at the time, although we now realize that many of these adjustments are here to stay – or, at the very least, they are going to stick around for longer than we originally expected.

While the idea of working remotely existed prior to the arrival of COVID-19, the pandemic certainly brought the concept front and center for many employers as it emerged as a national issue. It quickly became obvious that the way we work was changing and that companies were going to have to swiftly adapt to keep up. Read more.

Spend more time growing your business than running it.

As a business owner, you likely feel constant pressure to maximize revenues and create an efficient, scalable operating model that can also withstand the challenges and risks that come with running a business. However, according to a pulse survey on time management [1], most business owners spend an average of almost 70% of their time on administrative tasks and employee issues instead of strategic growth efforts.

What if you could increase new opportunities and revenue by maximizing the time you spend working on the business instead of in the business?

It starts with freeing you up from the operational complexities and responsibilities related to taxaccounting, and human resources (HR) — three essential functions of every business. Read more.Pulse Survey: Time Management, The Alternative Board, December 2015.

Global dealmakers 2023: Europe M&A market update

Global M&A markets have endured a difficult year, and European dealmaking has been no exception. Rising interest rates, high energy costs and geopolitical uncertainty have been just a few of the myriad challenges facing corporate and private equity dealmakers in recent months. The full report drills down into the details of last year’s M&A markets and explores the outlook for 2024.

In 2024, several structural and strategic drivers will be at play in the European M&A market. Read more.

Customs & Global Trade

Whether your business is expanding globally or simply growing sales by volume or location, Baker Tilly offers services that make global trade compliance easy, so you can blaze forward without losing momentum. Read more.

Site Selection

Autel Energy, an international company providing electric vehicle (EV) products and services, engaged Baker Tilly to assist in locating its first U.S. production facility as part of the EV movement being pushed by the federal government to create a nationwide network of electric vehicle charging stations. Read more.

Inflation Reduction Act: what’s new and why it matters

The Inflation Reduction Act (IRA) created game-changing opportunities through energy incentives and tax credits. In the year since the IRA was signed into law, there have been significant updates in guidance and regulations. Read more.

Transfer Pricing

In today’s global environment, transfer pricing matters have become a crucial discussion point for all corporate taxpayers. Multinational businesses face increasing scrutiny from tax authorities as ever-changing guidelines broaden regulatory requirements. Read more.

Connect with us

Ready to take next steps in going global? Contact our specialized team members below. We’re here to help!

Fred Massanova, East Region Managing Partner –

Gideon Gradman, Managing Director, Energy & Infrastructure Group – .

Robert Jaffe, Director of Business Development & BABCPHL Board Member –

Joseph C. Pellerite, Partner, Baker Tilly Advantage –

Ryan Onushco, Senior Manager, Business Development –

Making What’s Next in Medicine: Why Research at Penn Powers Many FDA-Approved Treatments

Since 2017, the FDA approved more than two dozen new therapies with roots at Penn Medicine — almost half of which are first-in-class for their indications. Becoming a hub for drug research and development took a lot more than luck.

The news reached Abramson Cancer Center (ACC) Director Robert Vonderheide, MD, DPhil, at 11 a.m. on August 30, 2017. It was official: That morning, the U.S. Food and Drug Administration (FDA) approved a Penn Medicine-developed personalized cellular immune therapy.

Six hours later, Vonderheide was standing atop a coffee counter in the atrium of the Perelman Center for Advanced Medicine, addressing hundreds of jubilant faculty and staff members who had gathered for a now-iconic “flash mob” celebration of the milestone. Carl June, MD, and a team of scientists, physicians, and other dedicated staff had together turned a dream of using patients’ own immune cells to treat their cancer, into a reality.

Vonderheide called the discovery “a 20-year overnight sensation.” It would be a defining moment for Penn’s identity as a place that incubates and brings to life some of the most transformative modern medical advancements.

The FDA approval of chimeric antigen receptor (CAR) T cell therapy didn’t happen at Penn Medicine by chance. Nor did the others that followed. Since that day, other medical innovations and research that had been underway at Penn Medicine directly influenced at least two dozen more FDA approvals granted to cancer drugs and other medical technologies — giving the stamp of safety and effectiveness needed for these treatments to be widely available to patients outside of clinical trials. Eleven of the medical advancements documented to date represent the first FDA approvals in their classes: eight under cancer, two under gene therapy, and the revolutionary mRNA technology that powers COVID-19 vaccines around the world.

Penn Medicine faculty may lead this crucial work at different points across the continuum of discovery, from conducting pivotal discovery science in the lab which leads to licensing of compounds and technologies by commercial partners, to leading clinical trials of new therapies initially developed outside of Penn.

The list of Penn-linked FDA approvals is growing with each passing year, and for good reason. Science has shifted toward more discoveries based on the underlying mechanism of disease, especially in new cancer drug discovery. Through a particularly robust clinical trial and commercialization infrastructure, Penn has further worked to smooth every part of the path from idea to implementation. And to ensure that state-of-the-art treatments reach the patients who need them, Penn Medicine teams have also kept focus on equity and access during clinical trials and after therapies are approved.

In the long view, Penn’s emergence as a hub for medical advancements that lead to drug research and development is a credit to both the culture and strategic choices going back decades, says Jon Epstein, MD, executive vice dean and chief scientific officer in the Perelman School of Medicine.

“Our leadership has been judicious about investing in a broad portfolio across a pipeline of development that might take 20 or 30 years,” Epstein says. “People here embrace a no-risk, no-reward approach — they aren’t afraid to take the long view and realize you have to back many different ideas to end up with just a few breakthrough therapies.”

Reducing Barriers to Translational Research

Hiring Carl June — whose belief that the immune system could be trained to fight cancer was derided by naysayers — in 1999 is one of the risks Epstein references. At the time, nobody predicted June’s work would change the entire trajectory of cancer care.

June began studying CAR T cell therapy in cancer in the late 1990s, and as signs of success grew, so did the breadth of collaborators at Penn Medicine and Children’s Hospital of Philadelphia (CHOP) who brought the method into clinical trials. It would take nearly two decades to achieve FDA approval of the therapy in 2017 as a treatment for advanced acute lymphoblastic leukemia. The groundbreaking technique involves taking T cells — part of the immune system — from a patient’s blood and engineering them to produce CARs before reinfusing them into the body. These new receptors latch onto unique antigens on the patient’s tumor cells, killing them. Marketed by Novartis as Kymriah, the first CAR T cell therapy has proved lifesaving for many patients whose cancer has relapsed or failed to respond to other therapies. It has since garnered two additional approvals from the FDA to treat other forms of cancer.

Similar stories have played out on campus over and over. Jean Bennett, MD, PhD, and Albert Maguire, MD, were also “risky” hires whose ambitions vexed skeptics when they joined Penn’s Scheie Eye Institute in 1992. But their determination and decades of work from basic science through to clinical trials at Penn and CHOP, paid off; in December 2017, less than four months after approving CAR T, the FDA approved the married team’s treatment for a rare form of congenital blindness called Leber congenital amaurosis. Marketed as Luxturna, the therapy restores patients’ eyesight by injecting a corrective gene directly into their eyes via a viral vector. It was the nation’s first commercialized gene therapy — a term that encompasses a collection of techniques to modify a patient’s DNA — for a genetic disease.

Eighteen months later, approval followed for Zolgensma, a gene therapy using a viral vector developed in the lab of James Wilson, MD, PhD, director of Penn’s Gene Therapy Program and Orphan Disease Center, and studied in trials at CHOP, to correct spinal muscular atrophy — the number one genetic cause of infant mortality.

And in the most ubiquitous novel advance tied to Penn Medicine, in August 2021 the FDA gave its first full approval to an mRNA-based COVID-19 vaccine, which uses technology discovered more than 15 years earlier by longtime research partners Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research, and Katalin Karikó, PhD, an adjunct professor of Neurosurgery.

Recruiting faculty who dream big is essential to drug development, but there are other reasons Penn Medicine has connections to so many cutting-edge therapies. Among the top, says Vonderheide, is a strategic emphasis on translational research and eliminating barriers between laboratories and the clinic.

“Even our building design reflects that value. If you stand in the lobby of the Perelman Center for Advanced Medicine, you’re within 100 yards of the labs where discoveries are being made, the clinics where clinicians are designing clinical trials and patients are getting therapies, and the offices where executives are working out financial models,” he says. “We’re a unified, integrated system committed to making science real for patients.”

Financial investment from the health system is key to moving discoveries toward the clinic and helping more patients, Epstein adds, citing the Perelman School of Medicine’s Clinical Cell and Vaccine Production Facility — where cell and gene biotherapeutics are manufactured to meet regulatory standards — as an example.

“The health system invested in what was only basic research at the time to build the good manufacturing practices facility that is necessary to produce things like CAR T cells safely so they can be put back into humans,” he says. “Facilities like that cost a lot, and most medical schools can’t afford them. But at Penn Medicine we integrate our clinical and research missions intentionally, for the sake of the patients who don’t have the best clinical options today. We can’t afford not to invest back into ongoing scientific discovery.”

Expanding New Categories of Therapies Pioneered at Penn

The FDA approval of a drug doesn’t mean its development ends, particularly in young and still-unfolding categories like cell and gene therapy and mRNA technology. Research around the world has proliferated in these new realms, where Penn Medicine faculty are still striving to push the science forward.

While CAR T cell therapy has revolutionized treatment for hematologic malignancies, researchers are still striving to use it successfully against solid tumors; getting the treatment to penetrate solid masses is one challenge, and it is harder to find unique antigen proteins to target on solid tumor cells. Faculty members are examining ways to overcome these limitations, such as delivering CAR T cells regionally and testing multivalent CARs, which simultaneously bind to multiple targets.

Researchers are also pursuing universal “off-the-shelf” versions of CAR T, which would spare patients from having to donate their own T cells for engineering — saving precious time while ensuring an abundance of high-quality cells to work with. And many are studying CAR T therapy in conditions other than cancer — including Epstein, who is evaluating CAR T cells’ ability to treat fibrosis, which can affect any organ and is a major driver of heart failure.

In terms of gene therapy, most activity to date has tackled rare diseases, but some faculty are on a mission to change that — like cardiologist Kiran Musunuru, MD, PhD, MPH, ML, director of the Genetic and Epigenetic Origins of Disease Program. Musunuru is applying the gene editing technology CRISPR to fight the leading cause of death worldwide: cardiovascular disease. He has found that modifying genes in the liver can permanently reduce a person’s cholesterol levels and protect against heart attack and stroke. Currently in a clinical trial in New Zealand and the U.K., this single shot could eventually work as a heart disease “vaccine.”

And when it comes to mRNA, “we’re working on every imaginable infectious disease,” says Weissman, who back in 2005, alongside Karikó, discovered how to modify mRNA so it could be used safely and effectively in vaccines and therapeutics. Even before COVID-19 struck, Weissman’s lab group had set up mRNA vaccine clinical trials for herpes, HIV, and influenza. The many avenues they are currently exploring include a universal flu vaccine that covers all 20 known subtypes of influenza virus and an all-in-one “pan-coronavirus” vaccine that would be effective against any new variants yet to emerge.

People suffering with a broad range of life-threatening illnesses today hold onto hope that tomorrow will bring a new therapy that will save their life. Across Penn Medicine, researchers are focused on developing new medicines to address their unmet needs.

“With Penn at the forefront, the application of these first-in-class therapies to a broader array of other diseases is just around the corner. Penn Medicine’s scientific impact — and the worldwide attention it commands — have never been greater,” says J. Larry Jameson, MD, PhD, executive vice president of the University of Pennsylvania for the Health System and dean of the Perelman School of Medicine. “It is a tremendous point of pride that innovation born within our laboratories is being deployed to save lives across the world, and we are committed to fostering breakthroughs that will continue to redefine medicine as the 21st century unfolds.”

More About Penn Medical Advancements Leading to FDA Approvals

The Path from Innovation to Implementation. Penn’s infrastructure in both supporting clinical research and forging commercial partnerships smooths the way from idea to approval.

Why New Cancer Treatment Discoveries are Proliferating. The approval of CAR T cell therapy ushered in a new era for cancer treatment.

Putting Biomedical Research Advances Within Reach. Treatments and vaccines are only useful in the hands of the people who need them.

Cross Border Financial Planning USA LLC: Top 10 Financial Considerations When Moving to the U.S.

Moving to a new country is exciting. But it may also be daunting as it requires many new undertakings, such as finding a place to live or opening a bank account, which can quickly become time-consuming and frustrating. Unsurprisingly, many leave the often complex financial and legal matters for a later date. The cost of doing so, however, can be high. To save time and hardship, Cross Border Financial Planning USA has put together 10 financial matters to consider when moving to the US. Whilst this brochure focuses on the intricacies of moving from the UK to the US, many of the same or similar principles apply when moving to the US from other countries.

  1. Reporting and paying tax

In the UK, most people only pay tax through the Pay As You Earn (PAYE) system, whereby tax is automatically deducted from their pay cheque and often there is no need to file a tax return. Although the US tax system is also Pay As You Earn, most people are still required to file a tax return each year and it is the individual’s responsibility to make sure they do so. Another difference is that the UK tax year runs from April 6th to April 5th, whereas the US tax year follows the calendar year from January 1st to December 31st.

  1. Investments

The most popular UK-based investments, such as exchange traded funds (ETF’s) and mutual funds, are likely to be treated as Passive Foreign Investment Companies (PFICs) by the US tax authority – the Internal Revenue Service (IRS). In the UK, it is very common to see ETFs and mutual funds held inside an Individual Savings Account (ISA) because an ISA is tax-free in the UK. In the US, however, the IRS does not recognize the tax-free status of an ISA and, as such, ETFs and mutual funds are taxed very inefficiently in the US and are complex investments to file on a US tax return.

For those who move back to the UK, a similar concept applies to US-based ETF’s and mutual funds. Unless they hold UK-reporting status or are held in an appropriate account, the gains will be subject to UK income tax when you return, rather than the more favorable capital gains tax rates. To avoid potential issues down the line, it is important to understand how an investment is taxed in both the US and UK, and make appropriate changes based on your current and future residence.

  1. Maintaining Property in the UK

For many people, the move to the US will not be permanent, either by their own choice or because their visa will not allow it. It is therefore common for people to maintain a property in the UK and rent it out. If you receive rental income from your UK property, this will be assessed for UK tax. This income also needs to be declared on your US tax return, and the double taxation treaty should allow you to use foreign tax credits to mitigate the risk of paying tax twice. If you sell your UK property whilst a resident in the US, then it is likely that you will be required to submit a non-resident Capital Gains Tax return to HMRC within 60 days of selling the property.

  1. Reporting Foreign Assets

Having a bank account in both the UK and the US is useful for those who travel between the two, but try to keep things simple by consolidating. If the aggregate values of your non-US bank accounts exceed $10,000 at any point in the year, you will need to file each account via the Foreign Bank Account Report (FBAR), and because this is an IRS requirement, there are significant penalties for failing to file.

There is an additional US annual reporting requirement for all foreign financial assets where the total value of these assets exceeds $50,000 at the end of the year, or $75,000 at any time during the year for individuals. These are the thresholds for US residents, which double for married couples.

  1. Be Smart on Currency

Transferring money straight from your UK bank to your US bank is often the easiest option, but almost never the best option. Utilizing a reputable currency broker or online currency company may be cheaper. Traditional banks often lack transparency, advertising zero fees or commissions, yet failing to make it clear how much they are making on the conversion rate itself.

  1. What to do with pensions and retirement plans

It is easy to forget about retirement accounts, but second to a person’s home, retirement accounts are often the next largest asset that a person owns. It is important not to neglect accounts left behind in the UK, and it’s equally important to be aware of the options available in the US. Understanding how these accounts will be treated if you leave the US will help provide a better outcome in the future.

  1. Rebuilding your credit score from scratch

Unless you have a poor credit score in the UK and are happy to be leaving it behind, starting fresh can be irritating. Not only can this work against you when a landlord reviews your application, but it can take years to build your score back to an equivalent level. The knock-on effect could still be felt several years later when applying for a mortgage. The most common complaint is the chicken and egg situation – you apply for a credit card to start building a credit score, but the credit card company rejects the application because you have no credit score. There are some banking and credit institutions that operate in both the UK and the US who will use your UK credit history when reviewing your US application, so that may be a good place to start. You can find out more information about how the US credit score system works at

  1. Wills and Trusts

If you have a will or power of attorney in the UK, check whether they will still carry out your wishes as intended, and whether they need updating. It will sometimes be necessary to have a will in both the UK and the US. The same is true for trusts, and in some cases, a trust in one country will be treated very differently in the other. For example, a UK trust can be brought into the US tax system if a trustee or

beneficiary becomes a US taxpayer. Similarly, a simple living trust in the US can become a UK resident trust if you return to the UK. Advice is key in this area before making any decisions about restructuring or making changes.

  1. Estate Planning

Estate taxes and inheritance taxes are different in both countries, and in the US, you have the additional complication of different state rules. At the federal level, the 2023 estate allowance is $12.92 million. A married couple who are both US citizens and long-term residents can protect $25.84 million from federal estate taxes. The unlimited marital deduction also enables any amount to be passed to a spouse free from federal estate taxes. In situations where one of the spouses is still deemed to be UK domiciled, which is not the same as being UK resident, the rules can be much less generous.

The estate allowance in the UK is far lower than in the US. In 2023, the allowance is £325,000 per person, with the potential to increase to £500,000 where a primary residence is passed onto children and grandchildren, as well as your estate being worth less than £2 million. Understanding domicile is key to understanding UK/US estate planning because it impacts not just which assets are liable to estate tax, but also whether you are liable for any estate tax at all.

  1. Seek advice if you are unsure

When moving countries there are many considerations over and above finding a place to live and adapting to a new environment. In some instances you may be able to find the answers yourself, but if you are unsure, work with professionals who have experience working with cross-border families. Living, earning, and investing in different countries may add a layer of complexity, but effective planning often presents financial opportunities.

Cross Border Financial Planning USA LLC is an investment adviser located and registered in Pennsylvania. Registration of an investment adviser does not imply any specific level of skill or training and does not constitute an endorsement of the firm by the State of Pennsylvania. Cross Border Financial Planning USA LLC only transacts business in states in which it is properly registered or is excluded or exempted from registration. A copy of Cross Border Financial Planning USA LLC’s current written disclosure brochure which discusses among other things, Cross Border Financial Planning USA LLC’s business practices, services, and fees, is available through the SEC’s website at:

Prior to making an investment decision, please consult with your financial advisor about your individual situation. Any mention of a particular security or type of security is not a recommendation to buy or sell that security. Investing involves risks including the possible loss of capital. Changes in tax laws or regulations may occur at any time and could substantially impact your situation. Cross Border Financial Planning USA are not tax or legal advisors, and you should discuss any tax or legal matters with the appropriate tax or legal professional.

Almac Group: Delivering Expertise Across the Drug Development Lifecycle and Offering Tailored Solutions to Clients Globally, in the Greater Philadelphia Region

Delivering Expertise Across the Drug Development Lifecycle and Offering Tailored Solutions to Clients Globally, in the Greater Philadelphia Region 

The Greater Philadelphia region has a long, storied history of being a global epicenter of healthcare. From groundbreaking cancer research conducted at leading institutions like the University of Pennsylvania, to the development of innovative biopharmaceuticals and gene therapies, the region boasts a diverse and talented group of global leaders dedicated to advancing health care and the life sciences.  

At Almac Group, we are proud to call Montgomery County home for our North American operations. We chose the Philadelphia region, specifically central Montgomery County, because this area supports our unique culture of delivering exceptional solutions and integrated services. 

The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Our innovative services range from R&D, biomarker discovery development and commercialization, API manufacturing, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) to commercial-scale manufacturing. 

We are a privately-owned, UK-based global company that has grown organically over the past five decades, currently employing over 6,500 highly skilled personnel across 18 facilities in Europe, the U.S. and Asia.  Founded by the late Sir Allen McClay, we are able to reinvest 100 percent of our profits back into the business – a strategy we are committed to. Our corporate structure provides long-term stability for our customers and for our employees while also allowing us to freely pursue investments designed to keep us at the forefront of our industry.  This is the recipe for Almac’s unique corporate culture, which marries the opportunity for employees to work in a genuinely caring and innovative workplace, while contributing to the valuable work of advancing human health. 

At Almac, we are trusted by leading biopharmaceutical companies around the world to provide a broad range of client services to support each critical phase of their drug development process. For example, last year, Almac was directly involved in the development of over 300 life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology and gene therapy. 

In the last five years alone, Almac has contributed to more than half of all globally approved New Molecular Entities and is currently supporting 30 percent of EU approved and pre-registered gene therapy products. Our position gives us a front-row seat on how drug development and clinical trials are continuing to evolve across the world. Our sponsors are increasingly expanding their pipelines, with particular focuses on new biologics, vaccines and other advanced therapy products. And of course, as we witnessed during the COVID-19 pandemic, the rapid deployment of vaccines and therapeutic drugs to combat the virus required unprecedented speed and efficiency in the drug development process. 

We are at the forefront of ensuring supply chain expertise and the capacity to support this evolution; and for us, that means we must continue to grow.  

Looking forward, our next three to five years in the Greater Philadelphia region are exciting. In the summer of 2022, we announced our plans to invest over $90 million on a range of expansion projects at our facilities in Montgomery County as well as create more than 350 new jobs in the Greater Philadelphia community. More recently, we were thrilled to reveal the largest of these projects – a $65 million, 100,000 square foot expansion of our clinical supply operations in Souderton. This capital plan will increase our clinical capacity at the site by 60 percent, providing additional cold, ultra-low and cryogenic storage and just-in-time processing capabilities.   

We will break ground in 2023, and upon completion, the added capacity will immediately support research organizations with their continued development of new biologics, gene and cell therapies and further advanced medicinal products.    

As we continue to grow in our work, we recognize and appreciate the support we have received and the strong relationships we have fostered as members of the British American Business Council. Our partnership with the BABC serves as a prime example of how successful collaborations are able to directly benefit communities and the life sciences industry, such as those in the Greater Philadelphia region. 

For more information and to keep up-to-date with latest news, follow us on Twitter and LinkedIn or visit  

EisnerAmper – Moving to Another Country Can Greatly Impact Your Tax Planning

Written By: Ragini Subramanian

There are many things that attract people to relocate to the U.S. and, by the same token, many U.S. citizens are lured to other jurisdictions. What is often forgotten is how the U.S. Treasury taxes U.S. citizens and green card holders who travel outside U.S. borders to live or work—temporarily or permanently—in foreign jurisdictions.

Impact on Income and Estate Taxes

U.S. citizens are subject to income tax in the U.S. on their worldwide income as well as U.S. tax return and foreign information return filing requirements. The country they call home—temporarily or permanently—after they leave the U.S. may also impose income tax on some of the same income that is taxed by the U.S.

A relief from double taxation is available in the U.S. either in the form of a foreign tax credit to offset taxes payable in the U.S., taking advantage of the foreign income exclusion provisions of the U.S. tax code, or availing double-tax relief afforded under a tax treaty between the U.S. and the foreign jurisdiction that is now the home. However, all this may not be as simple as it sounds:

  • The availability of a foreign tax credit may be limited (i.e., due to a smaller ratio of foreign source income to the U.S. source income, the foreign country tax rate is higher than that in the U.S., or the foreign tax is not eligible for foreign tax credit).
  • One may not meet the strict parameters of the foreign income exclusion rules (i.e., does not have a closer connection to the foreign country, does not meet the parameters of the tax home test, does not meet a continuous period of 330 days presence in a foreign country, or they are not present in the foreign jurisdiction for any period of 12 months).
  • No treaty exists between the U.S. and a given foreign country (e.g., U.S. and Hong Kong), or the existing treaty does not provide relief from double taxation for a particular item of income. Contributions to a retirement plan of an employer of a foreign country often fall under this.

What about transfer taxes, such as lifetime gifts and estate taxes upon passing. While there are several avenues to avoid double taxation with respect to income tax, there are not many options regarding gift tax or estate taxes. A U.S. citizen is subject to gift and estate taxes in the U.S. no matter where the U.S. citizen lives, works, gives away property or passes away. The country of residence’s gift, transfer or estate tax rules may also impose a gift or transfer tax. There are a far greater number of income tax treaties than there are gift and estate tax treaties between the U.S. and foreign countries that provide relief from double taxation. By the same token, fewer countries have gift or estate tax laws similar to those in the U.S. In many instances, gifts to close relationships—such as parents, children, brothers and sisters—are not subject to transfer taxes. That, however, does not take away the fact that the U.S. gift and estate tax laws remain applicable.

Therefore, it is very important to evaluate the income, gift and estate tax implications if you and your spouse have chosen to retire to another nation or if you are relocating to another country for a career opportunity.

Does Relinquishing Your U.S. Citizenship or U.S. Residency Make Sense?

You may think, forget it, I will just give up my U.S. citizenship or my green card to get away from the U.S. tax system. However, while this may work in some cases, it will not be the right option in all instances. If you are a U.S. citizen or considered a long-term resident of the U.S. and (1) meet a certain net worth threshold of more than $2 million, not inflation adjusted; (2) meet a tax liability threshold for 2022 average net income tax liability for the five tax years immediately before expatriation of not more than $178,000, inflation adjusted; or (3) simply do not or cannot certify that you are fully compliant with all applicable U.S. tax laws, you are considered a “covered expatriate” under a U.S. tax regime popularly known as the “exit tax.” With respect to certain assets, a covered expatriate is taxed in the U.S. before leaving the U.S. on the gain—after excluding up to $767,000 for 2022 plus inflation adjusted—as if the assets were sold at fair market value as of the date of expatriation. Other assets (e.g., pension plan, education savings plan) are taxed at the election and subject to a complex set of rules as of the date of expatriation or when income is received after a person leaves the U.S. In the latter case, the person may remain subject to tax in the U.S. and specific tax return filing requirements only on that income source and any other income source that may be considered U.S. source. The mistake many people make is returning to the U.S. after relinquishing their U.S. citizenship or green card and reestablishing U.S. tax residency, which places them back at square one.

The exit tax may not be that bad, but in the absence of proper planning, relinquishing your U.S. citizenship or green card can have other tax implications. The gift and estate tax exemption is lost if you forsake your citizenship. The exemption is $10 million, inflation-indexed ($12.06 million in 2022) for the years 2018 through 2025. Instead, you’re limited to a nonresident exemption of just $60,000. A 40% gift tax after only a $15,000 annual exclusion on gratuitous transfers of tangible property (e.g., cash, U.S. real property) located in the U.S. can make gift giving more expensive. The sale of U.S. real property located in the U.S. requires additional compliance under the U.S. Foreign Investment in Real Property Tax Act of 1980. A partnership interest in the U.S. partnership or foreign partnership deriving income in the U.S. may subject a nonresident to a multitude of tax withholding regimes depending on whether the partnership is engaged in passive activity or in an active trade or business in the U.S. It may also generate tax return filing requirement in the U.S.

Make Informed Decisions

Your assets and estate plan can be subject to a significant impact immediately and as you plan for the future if you move abroad. Before going overseas, consult with your tax professional about your plans and the tax implications.

Santander Commercial Banking – Santander Powers International Growth in a Complex World

The potential of global markets presents both promise and challenges. Today’s environment offers new opportunities to source suppliers, expand footprints, and streamline operations, but risks in many global markets are intensifying. Long-established trade relationships are in flux. Currency volatility poses a growing challenge. Some national economies are booming while others are facing historic upheavals. More than ever, global success demands local knowledge, careful management, and trusted partnerships.

Santander Commercial Banking focuses on helping clients make the most of international opportunities, from market entry to sophisticated global sourcing and export strategies. We bring valuable ideas, streamlined in-country execution, and a balanced perspective to capitalize on opportunities and manage risk in this new climate.

As one of the top banks in both the Eurozone and Latin America, we offer breadth in international banking capabilities—from simplifying cross-border treasury management to mitigating foreign exchange risk, from structuring trade finance to providing capital for growth or acquisitions—backed by the personal support of seasoned multilingual professionals.

Our dedicated global teams can customize coordinated cross-border solutions to address your corporate priorities and challenges.

Today’s global markets call for a financial partner with the experience to offer valuable insights and the ability to execute with local knowledge. Let us share our ideas to help you turn your objectives into results.

Click here for more information or contact Joe Sigle, at or 717-856-9437.

Club Level Feature – International Products Corporation – Specialty Chemical Manufacturer Since 1923

International Products Corporation (IPC) produces and markets specialty chemical products with emphasis on precision cleaners and assembly lubricants. IPC serves an international market with customers in the commercial, industrial, government and academic sectors. It reaches these markets through a combination of distributors, direct-sales and internet marketing. Currently, new products aimed at the consumer market are being developed. IPC also serves as a supplier of private-label products.

Founded in 1923, the company has been owned by Charles E. Granito since 1981. Rapid growth from 1981 to 1989 enabled the firm to move from Trenton, NJ, to a new custom-designed facility in Burlington, NJ, in 1990. On a four-acre site, this 20,000 ft2 building incorporates marketing, research, processing, packaging and warehousing functions that are key to IPC’s operations. Extraordinary steps were taken to make this facility safe for employees and the environment, and to assure that products made there meet the highest standards of quality. The on-site laboratory is equipped to expand quality and analytical work, allow for research on new and improved products and assist customers with technical testing.

In 1984, IPC opened IPCW, Inc., a subsidiary in the UK. IPCW distributes product for IPC throughout the European market. IPC also has distributors in China, India, Korea, Japan and Taiwan.

The full-line of precision cleaning products includes its flagship concentrated cleaner, Micro-90®. The line includes biodegradable, alkaline, acidic, neutral and enzyme cleaning products for a broad range of industries and applications. These include cleaning of labware, filter membranes, medical devices, pharmaceutical equipment and precision parts. All are registered with NSF as A1 cleaners.

P-80® Temporary Rubber Lubricants are unique formulated products for assembly of rubber and soft plastic parts (belts, bushings, grips, grommets, hoses, o-rings, seals) for the automotive, agricultural, appliance, aerospace, marine, pump and tool industries to name a few.

IPC is committed to making products that are water-based and to replace solvent and petroleum-based cleaners and lubricants. IPC avoids use of known carcinogens and hazardous chemicals, only using materials found on TSCA and EINESCS inventories. IPC maintains a ZERO discharge policy including wastewater, emissions and hazardous waste. And no product is considered highly toxic or corrosive. It is policy to keep abreast of environmental regulations such as removal of flame-retardants and certain metals (cadmium, mercury, chromium and lead) in products. IPC is an ISO-Certified Company.

IPC is an essential business.  Company operations have been continuous throughout the COVID-19 pandemic. Disinfecting surfaces to kill traces of microbes and disease is a critical concern right now. A common misconception is that simply disinfecting a surface is enough to sanitize it. This is not the case, cleaning and disinfecting are both important parts of a thorough sanitizing process. IPC’s products clean parts and surfaces first, allowing for proper sterilization after.

What is Cleaning? Cleaning refers to removing all dirt and soils from a surface. Detergents are used to clean surfaces. “Cleaning is the complete removal of…soil using appropriate detergent chemicals under recommended conditions.”

What is Disinfecting? Disinfecting refers to destroying or killing any germs, microbes or bacteria that are present on the surface. Disinfectants are used to accomplish this task.  “A disinfectant is a product which kills microbes without employing a soil removal action.”

Why do both? Surfaces must be properly cleaned prior to disinfecting. Removing traces of dirt, debris, and dust primes surfaces and equipment for disinfection. Soils can harbor germs and bacteria. Disinfection becomes less effective if surface soils are present.

What happens if I disinfect without cleaning? If a surface is disinfected before it is cleaned, the remaining soils can still contribute to the growth of harmful microbes and lead to further contamination. The residual soils may also serve as a barrier, preventing the disinfectant from reaching the surface and doing its job. Lingering soils on the surface may affect the active chemicals in a disinfectant, impacting their efficiency. If the surface is thoroughly cleaned first, and validated for cleanliness, the disinfection step becomes much more effective.

What are the steps for proper cleaning and disinfecting?

  1. Remove large debris
  2. Surface rinse with potable water
  3. Clean with a specialty detergent like Micro-90® or Micro® Green Clean
  4. Rinse thoroughly with potable water
  5. Disinfect
  6. Rinse again
  7. For regulated industries, validate the cleaning process

Contact IPC’s product specialists for more information about hard surface cleaners for manufacturing and laboratory applications.

Free product samples are available for testing. Request a sample for testing.

201 Connecticut Drive
Burlington, NJ 08016, USA
IPCW, Inc.
238 Green Lane
Green Lane Business Park
London SE9 3TL UK

KPMG – President Biden, Brexit and what’s next for British-American Business Council

President Biden, Brexit and what’s next for British-American Business Council

[British-American Business Council (BABC) Board Member and KPMG U.S. Principal Paul Harnick recently joined KPMG U.S.-U.K. Corridor Leader Howard Wiener and KPMG U.K.’s Michelle Quest for a discussion on the potential impact of the new U.S. administration’s policies and Brexit on BABC members’ business.]

Paul: What is the Biden administration’s proposed tax plan and what could it mean to a BABC member business?

Howard: During his campaign, Biden emphasized the need for certain policy changes, including infrastructure, clean energy, domestic manufacturing, rebuilding U.S. supply chains, housing, racial inequities, childcare, elder care and health care. To offset the costs of these goals, President Biden proposed changes to the Tax Code. President Biden’s campaign tax proposals were brief and high level. A few of the highlights affecting businesses and individual investors include:

  • Increase the top statutory corporate income tax rate from 21% to 28%
  • Create a new 15% corporate minimum tax on global book income of $100 million or more
  • Increase the tax rate on certain foreign income from 10.5% to 21%. Increase individual tax rates to 39.6% and tax capital gains and dividends for individuals with over $1 million in income at ordinary income rates

Over the coming months, we can expect additional proposals, as well as refinements to proposals, to be made. With Democratic control of the House of Representatives and effective control of the equally split Senate, Democrats are in control of the U.S. legislative agenda. However, whether, and to what extent, tax legislation will be passed is far from certain. As a general matter, Senate filibuster rules require 60 votes for legislation to be considered for a vote, and convincing at least 10 Republicans to vote with the Democrats will be an extremely tall order. It’s important to note, though, that special “budget reconciliation” procedures allow some types of legislation, including tax legislation, to move through the Senate by only a majority vote without being subject to a filibuster. Yet, even in this scenario, the Democrats would need all 50 Democratic senators to agree to any legislation. This effectively leaves every Democratic senator with the power to veto any proposal. Given the broad spectrum of political philosophy among Democratic senators, one could expect negotiations and compromise around any proposals made by President Biden.

Paul: Can we expect a change in U.S. trade policy under a Biden administration?

Howard: Joe Biden has made clear that any trade deal between the U.S. and U.K. must be contingent upon respect for the Good Friday Agreement and prevent the return of a hard border. Given the current economic climate and uncertainty around the pandemic, it is unlikely that a U.K./U.S. trade deal will be done quickly. However, we can expect there will be further efforts to improve the U.K./U.S. economic relationship in the coming months and a deal in 2022 looks possible. More generally, there are not expected to be major trade liberalizations under a Biden presidency. The last few years have seen the U.S. taking a much harder stance on its trade relationship with China. This has been bipartisan.  Although the tone will likely change, many of the concerns of the Trump administration with respect to China are shared by President Biden and the Democratic Party.

Paul: Shifting to our other topic today – Brexit. Michelle, what has been the outcome?

Michelle: Since the U.K. voted in a national referendum to leave the European Union (EU) in 2016, businesses that operate between the U.K. and the EU have faced a significant level of uncertainty. Negotiations between the U.K. and EU ended in agreement on Christmas Eve to conclude the EU/U.K. Trade and Cooperation Agreement. The agreement now governs the economic and trading relationship between the U.K. and the EU.

The fact that an agreement was reached will be welcomed by many BABC members as it provides more certainty. However, businesses need to be aware that the agreement will not result in a static relationship between the U.K. and the EU. The agreement sets up a significant governance structure which will negotiate and determine how the agreement will be implemented. In particular, issues around financial services and data adequacy will be subject to further discussion. Furthermore, there is an automatic review of the agreement every five years.

Paul: What has been agreed?

Michelle: The agreement might be described as “skinny.” It focuses predominantly on goods, with most U.K. and EU goods not subject to tariffs or quotas.

There is little in the agreement for services. The provisions do not go much beyond existing EU practice, and, as a result, there will be challenges for service businesses to trade between the EU and the U.K.

Many citizens’ rights issues had already been covered in an earlier agreement and EU citizens living in the U.K. have until the end of June 2021 to secure their rights. BABC member businesses with mobile workforces need to be aware of the impact as the agreement ends the ‘freedom of movement [of people]’ between the U.K. and the EU.

Certain regulated sectors no longer have “passporting” rights, such as businesses operating in the pharmaceutical and financial services sectors.

Paul: What is the customs impact?

Michelle: The process at the U.K. and EU border has fundamentally changed. Customs declarations are now required on either side of the border and businesses will have to put further preparations in place, including holding registrations and having the data to support these declarations.

While the agreement means duty- and quota-free access to both markets, this applies only for goods that meet specific rules of origin. BABC member businesses should assess the impact of the rules of origin.

There are specific impacts from a customs perspective for Northern Ireland (NI). Customs duty will be due on British goods “at risk” of movement to the Republic of Ireland. A new UK Trader Scheme has been introduced.

Paul: What are the tax implications?

Michelle: The U.K. no longer has access, or needs, to comply with EU tax directives. In some cases, this may lead to additional taxation on certain transactions (for example, some inbound payments may be subject to withheld tax in the paying jurisdiction). The U.K. is no longer implementing DAC6 (the mandatory reporting rules) to the same extent as continuing EU members. U.K. implementation has been limited to one of the five categories (relating to information exchange and beneficial ownership).

The agreement contains provisions for coordination of social security. U.K. nationals travelling, working or living in the EU (and vice versa) will retain entitlements to some benefits. Cross-border workers and employers will only be liable to pay social security contributions in one state at a time.

Paul: What tax implications should BABC members be particularly aware of?

Michelle: There are several provisions in the U.S.-U.K. tax treaty favorable to U.K.-headed companies that require a party to be a resident of an EU member state. Ownership structure where U.K. companies have availed themselves to such provisions must be reviewed. Although there is hope that the U.S. and U.K. will negotiate amendments to account for Brexit, given the myriad of priorities announced by the Biden administration, any changes would not be expected in the short term.

Furthermore, in certain circumstances, consideration of the Limitation of Benefits clause of U.S. treaties may be necessary even where the payer or recipient is not a U.K. resident.

Paul: What is the impact on the U.K.’s economic outlook?

Michelle: KPMG estimates that with a trade deal between the U.K. and EU, U.K. GDP growth in 2021 could total 6.1%. If the U.K. had left the EU without an agreement, KPMG estimates U.K. GDP growth would have been lower, at 3.3%.

Paul: Are there any other impacts?

Michelle: The impacts of the U.K. leaving the EU are wide-ranging and the information we have covered during our discussion only briefly touches on a few of them. Given that the relationship between the U.K. and EU will not be static, businesses should follow developments, particularly in the coming months as the agreement is being implemented.

The Philadelphia Convention & Visitors Bureau

As the official tourism promotion agency for the City of Philadelphia, the Philadelphia Convention and Visitors Bureau is focused on positioning Philadelphia for success once international travel resumes, and the city can once again welcome overseas visitors.

To help facilitate recovery for the city’s hospitality and tourism businesses, the PHLCVB launched the PHL Health Pledge in partnership with the City of Philadelphia, the Commonwealth of Pennsylvania, the region’s renowned life sciences and medical community and institutions, along with the city’s hospitality business partners. Working together as one, Philadelphia’s hospitality community is displaying unstoppable ingenuity to ensure a safe return to travel, meetings, and events – key messages displayed in the PHLCVB’s new Unstoppable Philadelphia video.

PHL Health Pledge

The PHL Health Pledge is a long-term strategy that aligns the expertise and guidance from the PHLCVB’s Chief Health Advisor, Dr. David Nash, Dean Emeritus of the Jefferson College of Population Health and the PHL Health Advisors to establish best practices for reopening. The initiative demonstrates how Philadelphia is working together to introduce new clean and safe guidelines and leveraging our world-renowned life sciences industry by drawing upon their expertise to provide guidance and advice on how our tourism community can safely welcome visitors. The initiative is comprised of three key components:

  1. PHL Health Advisors, including:
    • Dr. Nash, serving as Chief Health Advisor, provides guidance directly to meeting planner customers and serve as a public spokesperson on behalf of the PHLCVB with regards to matters of public health and tourism.
    • The 20-member PHL Health Advisors sub-committee of PHL Life Sciences, act as an internal support team, providing guidance to the PHLCVB and our hospitality partners on health and safety standards as well as information on local medical advancements in the fight against COVID-19
  1. Resources for Safely Reopening:
    • Aggregated list of plans from national partners like U.S. Travel Association as well as many local tourism partners for review by potential visitors
    • PHL Hospitality Health Pledge signed by PHLCVB members and other local tourism-related businesses to show their commitment to new health and safety standards as they reopen for business. To date, over 100 PHLCVB members have signed the pledge, including hotels, restaurants, attractions and other businesses in the region. For a full list of members who have committed to a unified reopening of the city, visit PHL Hospitality Health Pledge.
  1. Continuing Education and Innovation:
    • On-going training and support for PHLCVB members to keep abreast of public health best practices to keep their hotels, attractions, and venues safe for visitors. Notably, the PHLCVB hosted a webinar for key customers with Dr. Nash, providing them with an opportunity to ask pertinent questions on how our industry should be adapting to changes brought on by the public health crisis.

Impact of Overseas, UK Visitation to Philadelphia

In 2019, there were over 76,000 hospitality-related jobs in Philadelphia County alone in 2019, making the industry one of Philadelphia’s largest and fastest growing employment sectors. Specifically, overseas visitation is critically important to Philadelphia’s overall leisure travel mix as overseas visitors tend to stay longer and spend more money while in market.

In 2018* the United Kingdom was Philadelphia’s #1 source market for overseas visitation, with over 112,000 visitors traveling to the city, and contributing over $91 million in direct spend. Prior to COVID-19, UK inbound-travel to Philadelphia grew by 3.4% from 2017 to 2018 with most UK visitors to Philadelphia arriving into PHL International. Visitation growth from the UK was supported by direct airlift to PHL from London, Manchester, Shannon and Edinburgh on American Airlines, and from Dublin on Aer Lingus.

For more insights on overseas visitation into Philadelphia and the economic impact on the leisure travel segment, view the PHLCVB’s Research and Resources.

↑ back to top

The BABCPHL recognizes our Club Level Members:

  • Almac
  • American Airlines
  • Baker Tilly
  • Cigna
  • Cigna
  • Duane Morris
  • EisnerAmper LLP
  • Faegre Drinker Biddle & Reath LLP
  • Forensic Resolutions
  • Johnson, Kendall & Johnson, Inc.
  • Johnson Matthey
  • Morgan Lewis
  • Olympus
  • Penn Medicine
  • Welsh Government